Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer

W. R. Bezwoda, C. S. Hesdorffer, R. D. Dansey

Research output: Contribution to journalArticle

Abstract

Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer. The first combination, consisting of methotrexate, mitoxantrone (Novantrone) and 5-fluoro-uracil (MNF), gave a response rate of 17/48 (35%). Cyclophosphamide + mitoxantrone (CN) gave a response rate of 20/31 (64%) while cyclophosphamide + mitoxantrone + vincristine (CNV) gave a response rate of 28/39 (72%). The response durations for the three regimens were 6 months for MNF, 7.5 months for CN and 11.5 months for CNV. The regimens were well tolerated with an approximately equal frequency of side-effects. Cardiotoxicity was infrequent, occurring in only 2 patients out of 118 studied.

Original languageEnglish (US)
Pages (from-to)465-467
Number of pages3
JournalSouth African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
Volume72
Issue number7
StatePublished - 1987
Externally publishedYes

Fingerprint

Mitoxantrone
Combination Drug Therapy
Breast Neoplasms
Cyclophosphamide
Vincristine
Therapeutics
Uracil
Methotrexate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer. / Bezwoda, W. R.; Hesdorffer, C. S.; Dansey, R. D.

In: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, Vol. 72, No. 7, 1987, p. 465-467.

Research output: Contribution to journalArticle

@article{4199483bd91b487a88b2f2de4ed1357d,
title = "Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer",
abstract = "Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer. The first combination, consisting of methotrexate, mitoxantrone (Novantrone) and 5-fluoro-uracil (MNF), gave a response rate of 17/48 (35{\%}). Cyclophosphamide + mitoxantrone (CN) gave a response rate of 20/31 (64{\%}) while cyclophosphamide + mitoxantrone + vincristine (CNV) gave a response rate of 28/39 (72{\%}). The response durations for the three regimens were 6 months for MNF, 7.5 months for CN and 11.5 months for CNV. The regimens were well tolerated with an approximately equal frequency of side-effects. Cardiotoxicity was infrequent, occurring in only 2 patients out of 118 studied.",
author = "Bezwoda, {W. R.} and Hesdorffer, {C. S.} and Dansey, {R. D.}",
year = "1987",
language = "English (US)",
volume = "72",
pages = "465--467",
journal = "South African Medical Journal",
issn = "0256-9574",
publisher = "South African Medical Association",
number = "7",

}

TY - JOUR

T1 - Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer

AU - Bezwoda, W. R.

AU - Hesdorffer, C. S.

AU - Dansey, R. D.

PY - 1987

Y1 - 1987

N2 - Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer. The first combination, consisting of methotrexate, mitoxantrone (Novantrone) and 5-fluoro-uracil (MNF), gave a response rate of 17/48 (35%). Cyclophosphamide + mitoxantrone (CN) gave a response rate of 20/31 (64%) while cyclophosphamide + mitoxantrone + vincristine (CNV) gave a response rate of 28/39 (72%). The response durations for the three regimens were 6 months for MNF, 7.5 months for CN and 11.5 months for CNV. The regimens were well tolerated with an approximately equal frequency of side-effects. Cardiotoxicity was infrequent, occurring in only 2 patients out of 118 studied.

AB - Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer. The first combination, consisting of methotrexate, mitoxantrone (Novantrone) and 5-fluoro-uracil (MNF), gave a response rate of 17/48 (35%). Cyclophosphamide + mitoxantrone (CN) gave a response rate of 20/31 (64%) while cyclophosphamide + mitoxantrone + vincristine (CNV) gave a response rate of 28/39 (72%). The response durations for the three regimens were 6 months for MNF, 7.5 months for CN and 11.5 months for CNV. The regimens were well tolerated with an approximately equal frequency of side-effects. Cardiotoxicity was infrequent, occurring in only 2 patients out of 118 studied.

UR - http://www.scopus.com/inward/record.url?scp=0023554595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023554595&partnerID=8YFLogxK

M3 - Article

C2 - 3660150

AN - SCOPUS:0023554595

VL - 72

SP - 465

EP - 467

JO - South African Medical Journal

JF - South African Medical Journal

SN - 0256-9574

IS - 7

ER -